Sun Pharma to Acquire InSite Vision
Sun Pharma has announced its one of the subsidiary entering into an agreement and plan of merger with InSite Vision […]
Say something
Tags: bacterial eye infections, Besifloxacin, BSE Sensex, Business/Finance, CEO, Chemistry, Cyclopropanes, drug delivery technology, DuraSite, DuraSite platform, health, Health/Medical/Pharmaceuticals, Insite, INSITE VISION INCORPORATED, Jerry St. Peter, Kal Sundaram, Latanoprost, M&A, ophthalmic products, ophthalmic solution, Organic chemistry, Organochlorides, owned subsidiary, Sun Pharmaceutical, SUN PHARMACEUTICAL INDUSTRIES LIMITED, United States, USD, Vice President and Head
-
-
Flipkart Health+ App Launched
06-04-2022
